Kura Oncology, Inc.

NASDAQ:KURA

Biotechnology

Healthcare
$7.35 +0.73%

+$0.07 today

Market cap
$675.31M
Beta
0.36
P/E (TTM)
-2.9
EPS (TTM)
-$3.32
52W Low $5.45High $12.49

Volume 1.66M

Average 1.66M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$64.06M

FY 2025 · Annual

Investing Cash Flow

-$13.10M

FY 2025 · Annual

Financing Cash Flow

$1.79M

FY 2025 · Annual

-98.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(130.47M)(135.84M)(152.63M)(173.98M)(278.67M)
Depreciation & Amortization558K759K849K848K(7.46M)
Deferred Income Tax4.6M0000
Stock-Based Compensation23.58M26.32M28.08M33.9M37.11M
Change in Working Capital(3.22M)(2.98M)7.82M286.17M184.44M
Accounts Receivables0000(6.74M)
Inventory0000(413K)
Accounts Payables(2.52M)(802K)10.33M15.2M4.5M
Other Working Capital(706K)(2.18M)(2.51M)270.97M187.1M
Other Non-Cash Items399K1.68M(8.94M)(12.62M)515K
Operating Cash Flow(104.55M)(110.06M)(124.82M)134.32M(64.06M)
Capital Expenditures(1.15M)(626K)(168K)(472K)(6.64M)
Acquisitions (Net)125.69K(33.25K)000
Purchases of Investments(445.66M)(270.66M)(409.82M)(659.05M)(761.59M)
Sales of Investments319.97M303.91M425.55M557.93M755.13M
Other Investing Activities(125.69K)33.25K000
Investing Cash Flow(126.84M)32.63M15.56M(101.59M)(13.1M)
Debt Repayment(7.25M)10M000
Common Stock Issued4.43M24.72M93.58M145.81M1.79M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(611K)3.84M1.21M8.6M0
Financing Cash Flow(3.44M)38.57M94.78M154.42M1.79M
Effect of Forex Changes00000
Net Change in Cash(234.82M)(38.87M)(14.48M)187.14M(75.36M)
Free Cash Flow(105.7M)(110.69M)(124.99M)133.85M(70.7M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$278.7M
+ D&A-$7.5M
+ Stock-Based Comp$37.1M
+ Deferred Tax$0
+ Working Capital$184.4M
+ Other Non-Cash$515.0K
= Operating Cash Flow-$64.1M
- Capex-$6.6M
= Free Cash Flow-$70.7M

Analysis

FY2025 free cash flow is -$70.7M. FCF conversion is 25.4% of net income. Operating cash flow was -$64.1M, with capex of -$6.6M. The largest bridge item is Working Capital at $184.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-3ASRS-3ASR filingNov 10, 2026
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
SC 13G/ASC 13G/A filingOct 27, 2026
4Statement of changes in beneficial ownershipSep 29, 2026

Does KURA generate free cash flow?

Kura Oncology, Inc. (KURA) generated -$70.70M of free cash flow in fiscal 2025.

How much operating cash flow does KURA produce?

Operating cash flow was -$64.06M, before capital expenditures of $6.64M.